HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.

被引：0
|
作者：
Hearn, Jason W. D.
AbuAli, Ghada
Magi-Galluzzi, Cristina
Reddy, Chandana A.
Chang, Kai-Hsiung
Klein, Eric A.
Sharifi, Nima
机构：
[1] Cleveland Clin, Dept Radiat Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Cleveland Clin, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44106 USA
[3] Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44106 USA
[4] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44106 USA
[5] Cleveland Clin, Dept Hematol & Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
[6] Cleveland Clin, Dept Canc Biol, Taussig Canc Inst, Cleveland, OH 44106 USA
[7] Cleveland Clin, Dept Urol, Taussig Canc Inst, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.156
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
156
引用
收藏
页数：1
相关论文
共 50 条
  • [21] HSD3B1 AND RESISTANCE TO CYP17A1 INHIBITION IN PROSTATE CANCER
    Reichard, Chad
    Almassi, Nima
    Russell, Carly
    Li, Jianbo
    Friedlander, Terence
    Sharifi, Nima
    JOURNAL OF UROLOGY, 2016, 195 (04): : E77 - E77
  • [22] Impact of a mutation in HSD3B1 gene on the effectiveness of androgenic deprivation treatment in prostate cancer
    Martin-Abreu, C. M.
    Ramos-Diaz, R.
    Mourani-Padron, I.
    Del Rosario-Garcia, B.
    Garcia-Marrero, R. D.
    Plata-Bello, A. C.
    Nazco-Casariego, G. J.
    Gutierrez-Nicolas, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S533 - S533
  • [23] Germline HSD3B1 Genetics and Prostate Cancer Outcomes
    Thomas, Lewis
    Sharifi, Nima
    UROLOGY, 2020, 145 : 13 - 21
  • [24] Inherited HSD3B1 polymorphisms and hormonal therapy resistance
    Antonarakis, Emmanuel S.
    LANCET ONCOLOGY, 2016, 17 (10): : 1347 - 1349
  • [25] HSD3B1, prostate cancer mortality and modifiable outcomes
    Freitas, Pedro F. S.
    Abdshah, Alireza
    McKay, Rana R.
    Sharifi, Nima
    NATURE REVIEWS UROLOGY, 2024,
  • [26] Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer
    Shiota, Masaki
    Fujimoto, Naohiro
    Sekino, Yohei
    Tsukahara, Shigehiro
    Nagakawa, Shohei
    Takamatsu, Dai
    Abe, Tatsuro
    Kinoshita, Fumio
    Ueda, Shohei
    Ushijima, Miho
    Matsumoto, Takashi
    Kashiwagi, Eiji
    Inokuchi, Junichi
    Uchiumi, Takeshi
    Oda, Yoshinao
    Eto, Masatoshi
    ANDROLOGIA, 2022, 54 (01)
  • [27] HSD3B1 genotype and abiraterone metabolism in patients with prostate cancer
    Alyamani, Mohammad
    Emamekhoo, Hamid
    Park, Sunho
    Taylor, Jennifer
    Almassi, Nima
    Upadhyay, Sunil
    Tyler, Allison
    Berk, Michael P.
    Hwang, Tae Hyun
    Grivas, Petros
    Rini, Brian
    Garcia, Jorge
    Auchus, Richard J.
    Sharifi, Nima
    CANCER RESEARCH, 2018, 78 (13)
  • [28] HSD3B1 PREFERENTIALLY UTILIZES PREGNENOLONE TO PROMOTE RESISTANCE TO ANTI-ANDROGENS IN PROSTATE CANCER
    Armstrong, Cameron
    Liu, Chengfei
    Lou, Wei
    Evans, Christopher
    Gao, Allen
    JOURNAL OF UROLOGY, 2018, 199 (04): : E368 - E369
  • [29] HSD3B1 genotype predicts castration resistance
    Clemens Thoma
    Nature Reviews Urology, 2020, 17 : 193 - 193
  • [30] HSD3B1 genotype predicts castration resistance
    Thoma, Clemens
    NATURE REVIEWS UROLOGY, 2020, 17 (4) : 193 - 193
12345